Paid Clinical Trials Springfield
Discover 203 paid clinical trials in Springfield, Illinois. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
BR-AMNon-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM
Sponsor:
BioStem Technologies
Location:
Code:
NCT06565156
Conditions
Non-infected Diabetic Foot Ulcer
Diabetic Foot
Diabetic Wound
Diabetic Foot Ulcer
Non-ischemic Diabetic Foot Ulcer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BR-AM
Standard Care
Dipraglurant with LevodopaDipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Sponsor:
Addex Pharma S.A.
Location:
Code:
NCT04857359
Conditions
Parkinson Disease
Dyskinesia, Drug-Induced
Dyskinesias
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Dipraglurant
Placebo
XEN1101A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Sponsor:
Xenon Pharmaceuticals Inc.
Location:
Code:
NCT05716100
Conditions
Focal Onset Seizures
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
XEN1101
Placebo
Observational StudyCollection of Samples USOPTIVAL Study
Sponsor:
Universal Diagnostics
Location:
Code:
NCT04792684
Conditions
Colorectal Cancer (CRC)
Advanced Adenomas (AA)
Eligibility Criteria
Sex: All
Age: 45 - 70+
Healthy Volunteers: Accepted
Interventions
Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Esprit BTKEsprit BTK Post-Approval Study
Sponsor:
Abbott Medical Devices
Location:
Code:
NCT06656364
Conditions
Chronic Limb-Threatening Ischemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Esprit BTK System
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Curvafix®Curvafix® Intramedullary System for Fixation of Pelvic and Acetabular Fractures, A Post Market Evaluation
Sponsor:
CurvaFix, Inc.
Location:
Code:
NCT05606042
Conditions
Pelvic Ring Fracture
Acetabular Fracture
Pelvic Fracture
Pelvic Fracture Acetabulum
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
IM Implant
Targeted TherapiesStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Sponsor:
AbbVie
Location:
Code:
NCT06548542
Conditions
Crohn's Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Risankizumab
Lutikizumab
ABBV-382
XEN1101A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Sponsor:
Xenon Pharmaceuticals Inc.
Location:
Code:
NCT05667142
Conditions
Primary Generalized Tonic-Clonic Seizures
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
XEN1101
Placebo
Enasidenib & Cedazuridine-DecitabineTesting the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT06577441
Conditions
Myelodysplastic Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Decitabine and Cedazuridine
Enasidenib
Venetoclax & ObinutuzumabA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Sponsor:
AbbVie
Location:
Code:
NCT06428019
Conditions
Chronic Lymphocytic Leukemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Venetoclax
Acalabrutinib
Obinutuzumab